Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCCAM on HRT alternatives

This article was originally published in The Tan Sheet

Executive Summary

In light of recent studies raising concerns about the safety of long-term hormone replacement therapy, NCCAM has issued a consumer advisory on alternative therapies for menopause symptoms. "At this time, there is not enough scientific evidence to determine whether these therapies are beneficial" or "as safe or safer than conventional drugs being used for menopausal symptoms, osteoporosis or heart disease," the Aug. 2 advisory warns. The center also notes it is funding research on "several botanicals that have shown promise for reducing menopausal symptoms," such as black cohosh, red clover, soy, dong quai and flax seed...

You may also be interested in...



Soy HRT Potential May Be As Complement Rather Than Substitute

Soy and purified soy isoflavones should be explored for complementary effects on hormone replacement therapy rather than for potential as an HRT replacement, according to speakers at a recent conference

US FDA Needs Plan For Addressing Inspection Backlog Post-COVID, GAO Says

Agency must plan to ensure that a growing backlog of surveillance inspections does not impede its ability to conduct inspections at high-risk sites, GAO official says.

Health And Wellness Trademark Review 2 March, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel